ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Clinical Trials Update: TRI-116: Molecular Glue Degraders for Dummies
The ALK-positive community is buzzing about a cutting-edge clinical trial currently recruiting for those with ALK-positive lung cancer. The experimental medication TRI-116 is an ALK molecular glue degrader. A Google search of “molecular glue degrader for cancer” will lead you to terms like proteasome, ubiquitin, and E3 ligase. If your eyes glaze over when you…
-
-
Six Facts About Clinical Research Participation for ALK-Positive Lung Cancer Patients
by Dr. Ken Culver, Executive Director and Medical Director, ALK Positive, Inc.
-
First Patient Dosed in Tri-611 Clinical Trial
The first patient has been dosed in the Phase 1/2 clinical trial evaluating TRI-611 for ALK-positive NSCLC, marking an important step forward in the development of new investigational therapies for the ALK-positive community.
-
Nuvalent Announces Submission of New Drug Application to the FDA for Neladalkib (NVL-655) in TKI Pre-treated Advanced ALK-positive NSCLC
Nuvalent has officially filed for FDA approval of NVL-655 (neladalkib), a promising next-generation ALK inhibitor for previously treated ALK-positive lung cancer. Backed by results from the ongoing ALKOVE-1 trial, this milestone could bring a powerful new treatment option one step closer for patients facing progression after prior ALK therapies.
-
-
Continuing ALK NSCLC TKI Treatment while on Chemotherapy Leads to Better Outcomes
A recent multi-center study examined outcomes for ALK-positive NSCLC patients who continued their ALK TKI while receiving platinum/pemetrexed chemotherapy after disease progression. The findings suggest that maintaining targeted therapy alongside chemotherapy may improve overall survival and reduce the risk of brain progression in certain patients.
-
Patient Perspective: Alternative Nuvalent drug for patients disqualified from NVL-655 due to liver toxicity
Jeff Sturm shares his experience accessing the investigational drug zidesamtinib through a single-patient IND after discontinuing the NVL-655 trial due to liver toxicity. His story highlights how physicians, researchers, and companies sometimes work together to explore additional options for patients.
-
Understanding Guardant360 Liquid Biopsy
Guardant360 Liquid is an advanced liquid biopsy that can detect extremely small amounts of tumor DNA circulating in the bloodstream. This technology allows doctors to identify important genetic changes even when tissue biopsies are difficult to obtain.
-
Honoring a Legacy: The John Pender Scholarship Fund
The John Pender Scholarship Fund, established in 2025, honors John’s legacy by supporting students connected to the ALK-positive community who are pursuing higher education. Each year, the scholarship helps a student working toward a future rooted in service, creativity, innovation, or care for others. The inaugural award supported a student pursuing nursing, continuing John’s spirit…
-
-
True or False: Test Your Knowledge of Clinical Trials
Clinical trials are often misunderstood. This short quiz explores common myths and facts about trials, helping patients better understand participation, safety, and the role research plays in improving outcomes for ALK-positive cancers.